ChrysCapital has appointed Dr. Vikas Gupta as Managing Director and Chief Executive Officer of Novartis India Limited (NIL) following its completion of a ₹1,376.8 crore acquisition of a 70.68% controlling stake in the pharmaceutical company. The leadership change, announced on July 29, 2026, signals the start of a new strategic phase for the Mumbai-based firm, which ChrysCapital aims to build into a leading branded-generics platform for the Indian market.

The transaction marks ChrysCapital’s first majority-controlled investment in the Indian pharmaceutical sector. Alongside Dr. Gupta’s appointment, Ramesh Ramadurai, Suchita Sharma, and Shashank Sinha have joined as Independent Directors, with Mr. Ramadurai serving as Chairperson of the Board. The move follows the exit of erstwhile promoter Novartis AG, which sold 1,74,50,680 equity shares via an off-market transfer dated February 19, 2026.

New Leadership and Board Structure

Dr. Gupta brings extensive experience to the role, aiming to leverage NIL’s legacy brands and scientific rigor. "NIL has earned its place in Indian healthcare over many decades," Dr. Gupta said. "Today we begin a new and exciting chapter... with ChrysCapital’s backing we have the resources and focus to grow our portfolio with purpose."

Kshitij Sheth, Managing Director at ChrysCapital Advisors, highlighted the importance of the new management team. "A strong management team is central to any successful organisation, and NIL is fortunate to have Dr. Vikas Gupta at the helm," he stated.

The updated Board composition includes:

• Managing Director & CEO: Dr. Vikas Gupta
• Chairperson: Ramesh Ramadurai (Independent Director)
• Independent Directors: Suchita Sharma, Shashank Sinha

Transaction and Ownership Details

The acquiring consortium comprises WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners. Post-acquisition, WaveRise Investments holds the majority stake at 56.45%, while ChrysCapital Fund X holds 10.32%. Two Infinity Partners holds 3.91% and is classified as a promoter group member. ChrysCapital X, LLC and OceanEdge Investments Limited act as Persons Acting in Concert (PACs) but hold no direct shares.

Novartis AG now holds nil shares and has been reclassified from 'promoter' to 'public' category shareholder under Regulation 31A(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosures were made pursuant to Regulation 29(2) by Novartis AG and Regulation 29(1) by the acquirers under the SAST Regulations, 2011.

Strategic Outlook

NIL operates across key therapeutic areas including pain management, calcium supplementation, gynaecology, neurosciences, and transplant immunology, with brands such as Voveran®, Calcium Sandoz®, and Tegrital®. The company plans to adopt a new name and corporate identity to reflect its separation from Novartis AG. ChrysCapital aims to leverage its sector expertise and network to support NIL’s growth, building on its track record of investing over $5.6 billion in more than 110 deals across India.

Novartis India Limited has completed its transition under new ownership by appointing Dr. Vikas Gupta as Managing Director and Chief Executive Officer and Bhagwat Singh Deora as Chief Financial Officer, effective July 29, 2026. The Board of Directors also approved critical commercial agreements with Novartis AG, including a royalty-free license for the Tegrital trademark and a five-year distribution agreement for pharmaceutical products, ensuring operational continuity after the ChrysCapital consortium acquired 70.68% of the equity share capital.

The appointments were made during the company’s 247th Board meeting held on July 29, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dr. Gupta, who initially joined as Additional Director and CEO, was immediately redesignated as Managing Director and CEO, subject to shareholder approval. Mr. Deora, a Chartered Accountant with over 20 years of experience in the pharmaceutical sector, joins from JB Pharma. These leadership changes follow the resignation of six outgoing directors, including former Chairperson Christopher David Snook and CFO Shilpa Shashank Joshi, as part of the governance restructuring triggered by the change in control.

Strategic Agreements and Brand Continuity

To secure its product portfolio post-acquisition, Novartis India executed three key agreements with Novartis entities on July 29, 2026. The most significant is the Tegrital Brand License Deed, which grants the company an exclusive, irrevocable, royalty-free, and non-assignable license to use the 'Tegrital' trademark in India. Under this deed, Novartis AG must automatically assign the trademark to the company at no additional cost, provided there is no material breach by the company. This ensures uninterrupted manufacturing, marketing, and sales of the Tegrital range of pharmaceutical products.

Additionally, the company signed a Distribution Agreement with Novartis Pharma Services AG, appointing it as the exclusive distributor to import and sell certain pharmaceutical products in India. This agreement has an initial term of five years, extendable by another five years subject to mutual consent. Supply prices are fixed for the first year, with subsequent pricing determined by a mechanism outlined in the contract. A separate Trademark Assignment and License Deed transferred ownership of other key brands, including Voveran, Macalvit, and Citromacalvit, to the company on a royalty-free basis.

Leadership and Committee Reconstitution

The new management team includes several senior appointments aimed at stabilizing operations and driving growth. Besides Dr. Gupta and Mr. Deora, the company appointed Jason D'Souza as President – M&A, Business Development & Investor Relations; Rahul Vijayvargiya as Chief Human Resource Officer; Masud Shaikh as Chief Supply Chain Officer; and Sumeet Rajput as President – Business Operations. All appointments took effect on July 29, 2026.

The Board also reconstituted its Risk Management Committee and Stakeholders Relationship Committee to align with the new director lineup. Shashank Sinha chairs the Risk Management Committee, while Ashok Bhatia leads the Stakeholders Relationship Committee. The company has adopted a new corporate email domain (nilpharma.co.in) and website to reflect its rebranding under the new management.

What the Numbers Show

The acquisition of 17,450,680 equity shares by the ChrysCapital consortium (WaveRise Investments Limited and ChrysCapital Fund X) solidifies their control with a 70.68% stake, reducing Novartis AG’s holding below the 10% threshold required for promoter classification. The execution of royalty-free brand licenses and long-term distribution agreements mitigates immediate revenue risks associated with the ownership transition, allowing the new management to focus on operational integration rather than renegotiating core supply chains. The appointment of experienced executives from major Indian pharmaceutical firms signals a strategy to leverage domestic market expertise for future growth.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE234A01025/d3c98de0-0d4d-488a-9ac5-31a79e4ea3a5.pdf